ICICI Securities Ltd. | Retail Equity Research Q3 revenues were more or less on expected lines despite higher-thanexpected price erosion in the US and demonetisation impact in the domestic market. In the US, almost all players reported pricing pressure in the base business. However, due to exclusivities, low base and new product launches, some players were able to register strong growth. I-direct pharma universe registered YoY revenue growth of 12% to | 38900 crore, driven by 11% growth to | 11427 crore in the US (select pack) and 10% growth in domestic formulations to | 8079 crore. EBITDA for the universe grew ~9%...